Start Your Discovery Campaign on the Right Foot
The quality of an antigen is critical to the success of every in vivo antibody discovery project. We built our antigen production capabilities to offer a reliable source of high-quality reagents and give our partners flexibility without sacrificing a streamlined workflow.
Twist’s Molecular Biology team has years of experience generating reagents for antibody discovery campaigns. We have optimized and proprietary techniques that generate robust immune responses for difficult target classes. Additionally, we can leverage our proprietary DiversimAb™ platform to induce immune responses against poorly immunogenic targets and improve antibody discovery timelines and success rates.
Start Your Discovery Campaign on the Right Foot
The quality of an antigen is critical to the success of every in vivo antibody discovery project. We built our antigen production capabilities to offer a reliable source of high-quality reagents and give our partners flexibility without sacrificing a streamlined workflow.
Twist’s Molecular Biology team has years of experience generating reagents for antibody discovery campaigns. We have optimized and proprietary techniques that generate robust immune responses for difficult target classes. Additionally, we can leverage our proprietary DiversimAb™ platform to induce immune responses against poorly immunogenic targets and improve antibody discovery timelines and success rates.
Immunization Expertise for any Antigen
Access Difficult-to-Express Antigens
Twist utilizes proprietary immunization vectors to directly express target antigens in mice, facilitating antibody discovery for challenging targets such as GPCRs and multi-spanning membrane proteins, and saving on antigen production costs and time. We can also leverage cell-based and subtractive immunization to enrich responses to cell-surface antigens.
Guidance from Antigen and Immunization Experts
The benefits of working with Twist include an experienced protein sciences team that reviews antigens and recommends critical sequence modifications before expression, optimized systems for rapid, ultra-high-yield protein production, high-level expression with appropriate post-translational modifications, and integrated antibody discovery capabilities.
Quick and Efficient Cell Line Generation
Our transient cell line generation approach allows our partners to quickly and efficiently succeed in their mAb discovery campaigns.
Rapidly Access 1000s of Off-the-Shelf Antigens
Thousands of recombinant protein antigens for popular targets are available on expedited timelines, so you can get your antibody discovery program going as quickly as possible.
Immunization Expertise for any Antigen
Access Difficult-to-Express Antigens
Twist utilizes proprietary immunization vectors to directly express target antigens in mice, facilitating antibody discovery for challenging targets such as GPCRs and multi-spanning membrane proteins, and saving on antigen production costs and time. We can also leverage cell-based and subtractive immunization to enrich responses to cell-surface antigens.
Guidance from Antigen and Immunization Experts
The benefits of working with Twist include an experienced protein sciences team that reviews antigens and recommends critical sequence modifications before expression, optimized systems for rapid, ultra-high-yield protein production, high-level expression with appropriate post-translational modifications, and integrated antibody discovery capabilities.
Quick and Efficient Cell Line Generation
Our transient cell line generation approach allows our partners to quickly and efficiently succeed in their mAb discovery campaigns.
Rapidly Access 1000s of Off-the-Shelf Antigens
Thousands of recombinant protein antigens for popular targets are available on expedited timelines, so you can get your antibody discovery program going as quickly as possible.
お客様の声
Title
Robert Carnahan 博士
Title
Twist は、私たちのプロジェクトに必要な質と量の DNA を迅速に提供できる唯一の人工 DNA プロバイダーです。人工遺伝子や抗体のベンダーとしてだけでなく、 Twist Biopharma は私たちの抗体開発の取り組みを補完してくれることを確信するにいたり、彼らの能力を活用するために関係を発展させることにしました。
ROBERT CARNAHAN,, PHD
Vanderbilt Vaccine Center（ヴァンダービルトワクチンセンター）副所長
我々のプラットフォームは、高難易度のがんを治療するための新規標的を迅速に生成・検証します。Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations.
JEFF GOLDBERG,, CEO
Immunitas Therapeutics
お問い合わせフォーム
抗体の専門家がお客様の開発ニーズについて詳しくお伺いいたします。難易度が高いと考えられる場合でもご遠慮なくお問い合わせください。
